FDA said it had found high levels of a possible cancer-causing impurity in some versions of the popular diabetes drug metformin.
The agency is reaching out to companies whose drugs had N-nitrosodimethylamine (NDMA) over accepted levels and will take appropriate action.
Bloomberg, which first reported the FDA’s findings, said that some recalls of metformin were expected as soon as this week.
Online pharmacy Valisure said in March that its independent tests showed high levels of NDMA in metformin made by 11 companies, including Amneal Pharmaceuticals Inc and Aurobindo Pharma Ltd.
NDMA contamination was responsible for the recall of heartburn drug Zantac.
Metformin is a prescription drug used to control high blood sugar in patients with type 2 diabetes.